Abbott is a global leader in in-vitro diagnostics with one of the broadest portfolios of businesses spanning every segment – point of care, immunoassay, clinical chemistry, hematology, blood screening, molecular and informatics. Molecular Diagnostics has been releasing oncology FISH and PCR assays since 1999. The team at Molecular Diagnostics brings their expertise, passion, and commitment to creating Companion Diagnostics solutions, with well-established CDx development models which embody emerging technology and innovative solutions to help deliver therapeutic success.



foundation medicine - partner logo

Foundation Medicine

Foundation Medicine is a pioneer in molecular profiling for cancer, working to shape the future of
clinical care and research. We collaborate with a broad range of partners across the cancer community
and strive to set the standard for quality, scientific excellence, and regulatory leadership. Our deep
understanding of cancer biology helps physicians make informed treatment decisions for their patients
and empowers researchers to develop new medicines. Every day, we are driven to help our partners find
answers and take action, enabling more people around the world to benefit from precision cancer care.




Bio-Techne Companion Diagnostics delivers precision medicine services spanning the continuum from biomarker discovery to post-market commercialization of a CDx product. We bring a 20+ year track record of success including the development of over 2700 assays for 570 targets, with over 50 clinical tests built for pharma and 15 CLIA tests. Our multi-omic, platform-agnostic approach, paired with clinical trial sample testing readiness at our CLIA labs and international regulatory expertise, allows us to offer customizable solutions so that a pharma partner can deliver novel treatments to the patients most likely to benefit, faster.